Chardan Capital Initiates Coverage On Gossamer Bio with Buy Rating, Announces Price Target of $160

Benzinga · 3d ago
Chardan Capital analyst Andreas Argyrides initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a Buy rating and announces Price Target of $160.